Victrex plc Q4 2025 Earnings Recap

Victrex reported a challenging fiscal year 2025, with a 12% increase in sales volume but a 21% decline in underlying profit before tax, driven by currency impacts and weaker medical revenue performance.

Key Takeaways

• Sales volume reached 4,164 tonnes, reflecting robust demand from value-added resellers and the Energy & Industrial sectors.
• Revenue growth was minimal at 1% to GBP 292.7 million, negatively impacted by currency fluctuations and a weaker medical spine segment.
• Implemented a profit improvement plan targeting over GBP 10 million in savings, leveraging recent foundational investments in infrastructure and technology.
• Operating cash conversion remained strong at 121%, supported by effective working capital management and reduced capital expenditures.
• Outlook for FY 2026 anticipates solid progress on both revenue and profitability, indicating resilience despite ongoing challenges.